Valeant Pharmaceuticals Intl Inc  

(Public, NYSE:VRX)   Watch this stock  
Find more results for VRX
14.39
+0.05 (0.35%)
Aug 18 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 14.17 - 14.54
52 week 8.31 - 32.74
Open 14.36
Vol / Avg. 10.47M/15.29M
Mkt cap 4.99B
P/E     -
Div/yield     -
EPS -3.27
Shares 347.33M
Beta -0.36
Inst. own 57%
Nov 6, 2017
Q3 2017 Valeant Pharmaceuticals International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 8, 2017
Q2 2017 Valeant Pharmaceuticals International Inc Earnings Release
Aug 8, 2017
Q2 2017 Valeant Pharmaceuticals International Inc Earnings Call - Webcast
Jun 20, 2017
Valeant Pharmaceuticals International Inc at Goldman Sachs Leveraged Finance Conference - Webcast
Jun 9, 2017
Valeant Pharmaceuticals International Inc at Barclays High Yield Bond and Syndicated Loan Conference - Webcast
Jun 7, 2017
Valeant Pharmaceuticals International Inc at Jefferies Healthcare Conference - Webcast
May 22, 2017
Valeant Pharmaceuticals International Inc at UBS Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -1.66% -24.89%
Operating margin 7.84% -5.85%
EBITD margin - 41.49%
Return on average assets -0.35% -5.21%
Return on average equity -3.90% -53.16%
Employees 21,500 -
CDP Score - D

Address

2150 Saint-Elzear Blvd W
LAVAL, QC H7L 4A8
Canada
+1-514-7446792 (Phone)
+1-514-7446272 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Officers and directors

Joseph C. Papa Chairman of the Board, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Paul S. Herendeen Chief Financial Officer, Executive Vice President
Age: 61
Bio & Compensation  - Reuters
Christina Ackermann Executive Vice President, General Counsel
Age: 52
Bio & Compensation  - Reuters
Thomas J. Appio Executive Vice President, Company Group Chairman, International
Age: 55
Bio & Compensation  - Reuters
William D. Humphries Executive Vice President, Company Group Chairman, Dermatology
Age: 50
Bio & Compensation  - Reuters
Thomas W. Ross Sr Lead Independent Director
Age: 66
Bio & Compensation  - Reuters
Richard U. DeSchutter Independent Director
Age: 76
Bio & Compensation  - Reuters
Fredric N. Eshelman Pharm.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
D. Robert Hale Independent Director
Age: 32
Bio & Compensation  - Reuters
Argeris N. Karabelas Ph.D. Independent Director
Age: 64
Bio & Compensation  - Reuters